61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
61%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
61%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
UCB SA
Closed
Sector Healthcare
185.9 0.68
Overview
Share price change
24h
Min
185.1
Max
186.45
Income | 104M |
|---|---|
Sales | 127M 2.8B |
P/E Sector Avg | 78.783 87.008 |
EPS | 2.09 |
Dividend yield | 0.981 |
Profit margin | 3.728 |
EBITDA | 652M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +19.23 upside |
Dividend yield Sector Avg | 0.98% 2.48% |
|---|---|
Next Earnings | 27 Feb 2025 |
Market Cap | 778M 35B |
|---|---|
Previous open | 185.22 |
Previous close | 185.9 |
News Sentiment
By Acuity
50%
50%
175 / 392 Healthcare
UCB SA Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
UCB SA Forecast
Price Target
By TipRanks
19.23% upside
12 Months Forecast
Average 94.86 EUR 19.23%
High 125 EUR
Low 74 EUR
Based on 7 Wall Street analysts offering 12 month price targets forUCB SA - Dist in the last 3 months.
Sentiment
By Acuity
175 / 392 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
EBITDA
Operating profit
$
About UCB SA
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
